(VIANEWS) – The NASDAQ opens in less than five hours and Amicus Therapeutics‘s pre-market value is already 7.56% up.
Amicus Therapeutics’s last close was $11.24, 18.79% below its 52-week high of $13.84.
The last session, NASDAQ ended with Amicus Therapeutics (FOLD) sliding 3.19% to $11.24. NASDAQ slid 0.74% to $11,630.51, following the last session’s downward trend on what was a somewhat down trend trading session.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Earnings Per Share
As for profitability, Amicus Therapeutics has a trailing twelve months EPS of $-1.07.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.68%.
Sales Growth
Amicus Therapeutics’s sales growth is 5% for the current quarter and 10.3% for the next.
Moving Average
Amicus Therapeutics’s worth is way below its 50-day moving average of $12.63 and under its 200-day moving average of $11.24.
Volume
Today’s last reported volume for Amicus Therapeutics is 3035624 which is 22.91% below its average volume of 2110230.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 323.29M for the twelve trailing months.
More news about Amicus Therapeutics (FOLD).
